Skip Navigation


JAC Advance Access originally published online on July 22, 2005
Journal of Antimicrobial Chemotherapy 2005 56(3):507-512; doi:10.1093/jac/dki269
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
56/3/507    most recent
dki269v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cocuaud, C.
Right arrow Articles by Imbert, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cocuaud, C.
Right arrow Articles by Imbert, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press 2005

Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms

Christophe Cocuaud, Marie-Hélène Rodier, Gyslaine Daniault and Christine Imbert*

Laboratoire de Parasitologie et Mycologie Médicales, Centre Hospitalier Universitaire La Milétrie, BP 577, 86021 Poitiers Cedex, France

Received 8 March 2005; returned 20 May 2005; revised 27 May 2005; accepted 30 June 2005

* Corresponding author. Tel: +33-05-49-44-39-59; Fax: +33-05-49-44-39-08; E-mail: Christine.Imbert{at}univ-poitiers.fr

Objectives: Candidiasis can be associated with the formation of biofilms on bioprosthetic surfaces and the intrinsic resistance of Candida albicans biofilms to the most commonly used antifungal agents has been demonstrated. In this study, we report on the antifungal activity of caspofungin at two different concentrations, on C. albicans and Candida parapsilosis biofilms with different ages of maturation.

Methods: Fifteen strains of C. albicans (10 strains susceptible to fluconazole in vitro and five strains resistant to this antifungal agent) and six strains of C. parapsilosis (all were susceptible to fluconazole in vitro) were studied. The antifungal activity of caspofungin was assessed by looking for a significant inhibition of the metabolic activity of yeasts within biofilms. Biofilms of Candida were produced in vitro, on silicone catheters.

Results: Caspofungin used at MIC did not modify the metabolic activity of C. albicans, whatever the maturation age of the biofilms. The same concentration of caspofungin significantly reduced the metabolism (P ≤ 0.001) of 25% (biofilms of 48 h) to 50% (biofilms of 2 h) of the C. parapsilosis yeasts. The use of a therapeutic concentration of caspofungin (2 mg/L) significantly decreased (P ≤ 0.001) the metabolism of all the strains of C. albicans and C. parapsilosis tested, independently of the biofilm maturation age. This potent antifungal activity of caspofungin on C. albicans biofilms was observed independently of the yeast susceptibility to fluconazole.

Conclusions: This study demonstrated that caspofungin used at MIC was not sufficient to reduce C. albicans biofilms, but it suggested an activity on C. parapsilosis biofilms depending on their maturation age. This study also indicated that caspofungin used at 2 mg/L could be a good candidate in the prevention of candidiasis associated with silicone medical devices. Our results also suggested that fluconazole resistance of yeasts did not affect caspofungin activity.

Keywords: candidiasis , catheters , antifungals , metabolism , echinocandins


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
D. Trofa, A. Gacser, and J. D. Nosanchuk
Candida parapsilosis, an Emerging Fungal Pathogen
Clin. Microbiol. Rev., October 1, 2008; 21(4): 606 - 625.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
E. Cateau, M.-H. Rodier, and C. Imbert
In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth
J. Antimicrob. Chemother., July 1, 2008; 62(1): 153 - 155.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. Katragkou, A. Chatzimoschou, M. Simitsopoulou, M. Dalakiouridou, E. Diza-Mataftsi, C. Tsantali, and E. Roilides
Differential Activities of Newer Antifungal Agents against Candida albicans and Candida parapsilosis Biofilms
Antimicrob. Agents Chemother., January 1, 2008; 52(1): 357 - 360.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. S. Melo, A. L. Colombo, and B. A. Arthington-Skaggs
Paradoxical Growth Effect of Caspofungin Observed on Biofilms and Planktonic Cells of Five Different Candida Species
Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3081 - 3088.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. Perumal, S. Mekala, and W. L. Chaffin
Role for Cell Density in Antifungal Drug Resistance in Candida albicans Biofilms
Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2454 - 2463.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
I. Bruzual, P. Riggle, S. Hadley, and C. A. Kumamoto
Biofilm formation by fluconazole-resistant Candida albicans strains is inhibited by fluconazole
J. Antimicrob. Chemother., March 1, 2007; 59(3): 441 - 450.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.